Kura Oncology, Inc. KURA
We take great care to ensure that the data presented and summarized in this overview for Kura Oncology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KURA
View all-
Black Rock Inc. New York, NY6.97MShares$45.7 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.8MShares$38 Million0.71% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.08MShares$33.3 Million1.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.82MShares$31.6 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.45MShares$29.2 Million0.63% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.56MShares$23.3 Million1.45% of portfolio
-
State Street Corp Boston, MA3.35MShares$21.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.27MShares$21.5 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.57MShares$16.8 Million0.84% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.37MShares$15.5 Million0.01% of portfolio
Latest Institutional Activity in KURA
Top Purchases
Top Sells
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Insider Transactions at KURA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 21
2025
|
Faheem Hasnain |
SELL
Open market or private sale
|
Direct |
22,682
-48.61%
|
$181,456
$8.0 P/Share
|
|
Mar 21
2025
|
Faheem Hasnain |
BUY
Exercise of conversion of derivative security
|
Direct |
22,682
+32.71%
|
$136,092
$6.32 P/Share
|
|
Jan 28
2025
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
4,949
-1.35%
|
$34,643
$7.87 P/Share
|
|
Jan 28
2025
|
Brian T. Powl Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,583
-2.58%
|
$11,081
$7.87 P/Share
|
|
Jan 28
2025
|
Francis Burrows Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,166
-4.85%
|
$15,162
$7.87 P/Share
|
|
Jan 28
2025
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,817
-7.84%
|
$12,719
$7.87 P/Share
|
|
Jan 28
2025
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,281
-3.2%
|
$50,967
$7.87 P/Share
|
|
Jan 28
2025
|
Mollie Leoni Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,963
-1.36%
|
$34,741
$7.87 P/Share
|
|
Jan 02
2025
|
Mollie Leoni Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+33.16%
|
-
|
|
Jan 02
2025
|
Brian T. Powl Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+43.02%
|
-
|
|
Jan 02
2025
|
Teresa Brophy Bair Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,250
+28.64%
|
-
|
|
Jan 02
2025
|
Thomas James Doyle SVP, Finance & Accounting |
BUY
Grant, award, or other acquisition
|
Direct |
42,500
+20.7%
|
-
|
|
Nov 18
2024
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
526
-2.22%
|
$8,416
$16.03 P/Share
|
|
May 20
2024
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,615
-3.65%
|
$57,530
$22.15 P/Share
|
|
Jan 30
2024
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,825
-11.06%
|
$101,325
$21.55 P/Share
|
|
Jan 29
2024
|
Stephen Dale Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,158
-7.3%
|
$121,686
$17.8 P/Share
|
|
Jan 29
2024
|
Kathleen Ford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,496
-6.48%
|
$25,432
$17.8 P/Share
|
|
Jan 29
2024
|
Teresa Brophy Bair Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,053
-2.89%
|
$34,901
$17.8 P/Share
|
|
Jan 29
2024
|
Thomas James Doyle SVP, Finance & Accounting |
SELL
Open market or private sale
|
Direct |
2,318
-1.56%
|
$39,406
$17.8 P/Share
|
|
Jan 24
2024
|
Troy Edward Wilson President and CEO |
SELL
Open market or private sale
|
Direct |
91,052
-95.95%
|
$1,821,040
$20.23 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 22.7K shares |
|---|---|
| Grant, award, or other acquisition | 181K shares |
| Open market or private sale | 48.6K shares |
|---|